To stump up $300k at this point of the journey is a great sign.
At 3.7c the market has priced in meagre domestic growth and zero revenue from international expansion.
10M would put him in the Top20.
With this commitment it suggests the opportunities are on the not to distant horizon.
According to their announcements, PDX Inc integration should be complete in the coming weeks. This opens up 15% of pharmacies in the US (10,000+).
Last month they also received approval to integrate with the UK dispense systems, of which there are only 3.
I suspect into early next year EBOS will get return on their 5.75c per share investment.
Ann: Appendix 3Y Director's Interest Notice, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.010(2.25%) |
Mkt cap ! $250.8M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.5¢ | 44.5¢ | $683.4K | 1.508M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7000 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 34999 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| MDR (ASX) Chart |